Physician profile
Thomas Waller
NPI 1760410187
$3,178.86
in general payments reported to CMS, 2019-2025
25 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $241 · 2021: $18.91 · 2022: $52.28 · 2023: $276 · 2024: $687 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $974.43 | 2019-2025 | |
| Amgen INC. | $292.22 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $269.94 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $209.92 | 2019-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $181.84 | 2019 | |
| Astellas Pharma US INC | $175.15 | 2019-2021 | |
| Amarin Pharma, INC. | $168.03 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.04 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $104.77 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.81 | 2019-2025 | Lifevest |
| Heartflow, INC. | $89.34 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals International, Plc | $85.43 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $80.70 | 2019-2025 | Camzyos |
| Sun Pharmaceutical Industries INC. | $64.66 | 2019 | |
| Novo Nordisk INC | $49.20 | 2022-2024 | Ozempic |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45.04 | 2019-2020 | |
| Gilead Sciences, INC. | $38.00 | 2019 | |
| Inspire Medical Systems, INC. | $20.02 | 2025 | Inspire |
| Kiniksa Pharmaceuticals, Ltd. | $19.89 | 2023 | Arcalyst |
| Baxter Healthcare | $18.70 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $17.49 | 2023 | Nexletol |
| Pfizer INC. | $16.75 | 2019 | |
| Getinge USA Sales, LLC | $14.54 | 2024 | Cardiohelp |
| Arbor Pharmaceuticals, INC. | $14.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Waller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.